MediRita
MediRita is an AI-driven drug discovery company that innovates the drug development paradigm using its proprietary Multi-omics Network AI (MuN-AI) platform. The company accelerates preclinical drug development by integrating and analyzing complex multi-omics big data related to human biology, providing objective and scientific evidence for candidate selection. Its key products include a multi-omics network database and AI technologies for drug candidate design, pharmacological effect prediction, and side effect forecasting. MediRita has achieved significant milestones such as multiple patents, software quality certifications, and government awards, positioning itself as a leading AI biotech innovator in South Korea with a focus on efficient and cost-effective drug discovery.
MediRita
MediRita is an AI-driven drug discovery company that innovates the drug development paradigm using its proprietary Multi-omics Network AI (MuN-AI) platform. The company accelerates preclinical drug development by integrating and analyzing complex multi-omics big data related to human biology, providing objective and scientific evidence for candidate selection. Its key products include a multi-omics network database and AI technologies for drug candidate design, pharmacological effect prediction, and side effect forecasting. MediRita has achieved significant milestones such as multiple patents, software quality certifications, and government awards, positioning itself as a leading AI biotech innovator in South Korea with a focus on efficient and cost-effective drug discovery.